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Abstract 
The Nucleoside Hydrolase (NH36) is the main marker of the FML complex of Leishmania donovani, antigen of the licensed 
Leishmune® vaccine for prophylaxis of canine visceral leishmaniasis. As a DNA vaccine in mice, it induces a TH1 immune 
response. We vaccinated mongrel dogs with the VR1012NH36 vaccine for prophylaxis and immunotherapy against a high dose 
Leishmania chagasi infection (7 x 108 infective amastigotes). The untreated controls developed more symptoms, higher 
parasite/lymphocyte ratio, smaller DTH reactions, lower proportions of NH36-specific CD4+ cells and sustained NH36-specific 
CD8+ cell counts than dogs of the prophylaxis group. In the immunotherapy treated group, enlarged DTH reactions, enhanced 
CD4+ and sustained CD8+ lymphocyte proportions were also detected, however, without reduction of symptoms or 
parasite/lymphocyte ratio, indicating that the vaccine was sufficiently potent to prevent but not to control the disease. Both 
treatments determined higher survival rates. Anti-FML antibodies increased in vaccinated and control dogs while anti-NH36 
antibodies were only increased in vaccinees (p= 0.000). The parasite load of an untreated survivor control dog (638.05 parasites) 
felt outside the IC95% of that of vaccinated dogs (32.02, IC95% 9.45-64.59) suggesting that both vaccination treatments 
succeeded in reducing the Leishmania infective burden. Accordingly, an untreated control dog showed lower levels of IFN Ȗ-ȕ, 
IL-2, IL4 but not IL-10 ȕ actin-relative quantification. We conclude that the VR1012-NH36 vaccine induces strong prophylactic 
protection and a milder immunotherapeutic effect against a high dose canine experimental infection with Leishmania chagasi
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Vaccination with the FML-saponin Leishmune® vaccine is efficient in prevention [1,2], immunotherapy 
[3,4] and in blocking the transmission of canine visceral leishmaniasis (CVL) between dogs and to humans [5]. 
NH36, a nucleoside hydrolase of 34.3 kDA and 314 amino acids, is the main antigenic marker of the FML complex 
[6]. It cleaves nucleosides from imported DNA to release free purine or pyrimidic bases for Leishmania replication 
and according to this very relevant function it has been recently recognized as an important and conserved 
phylogenetic marker of the Leishmania genus [7]. As a DNA vaccine (VR1012-NH36) in mice it induced 88% of 
protection, 91% of curative potential against visceral and 65% of protection against coetaneous leishmaniasis, 
developing a TH1 immune response [8].  
In this work we used 19 SRD dogs (4 months old), of 4 different broods, that were vaccinated against 
rabies, canine distemper, Type 2 Adenovirus, Coronavirus, Parainfluenza, Parvovirus and Leptospira and treated 
with anti-helminthic drugs. All dogs were healthy and seronegative for Leishmania antibodies in the FML-ELISA 
assay [9]. Aiming to avoid any bias based on genetically determined susceptibility [10], each brood was randomized 
by draft into 3 experimental groups (saline, prophylaxis and immunotherapy). For prophylaxis, 6 dogs were 
vaccinated with 3 doses of 750 ȝg of VR1012-NH36 plasmid, through the im route on days 0, 21 and 42, while the 
other 13 dogs received only saline. On day 67, all the animals were challenged with 7 x 108 amastigotes from a L 
chagasi strain maintained for 3 passages in hamsters and originally isolated from an infected dog. On day 160, all 
the 13 untreated dogs were already Leishmania-seropositive and symptomatic. Six of them were treated for 
immunotherapy with 3 doses of  750 ȝg of theVR1012NH36 vaccine, while the other 7 remained as untreated 
controls. The sera of all animals was assayed for the presence of anti-NH36 and anti-FML antibodies [9] and the 
cellular immune response was evaluated by the assessment of the DTH response against leishmanial lysate and of 
the proportion of CD4+ and CD8+ specific lymphocytes after in vitro proliferation of PBMC with 0.5 ȝg NH36. 
Dogs were also monitored for their clinical symptoms scores and for their parasite/lymphocyte ratio in Giemsa 
stained smears obtained after fine needle lymph-node punctures. All cohorts were monitored until day 517. At the 
end of the experiment, the parasite load of the survivor dogs was evaluated in PBMC and the cytokine expression in 
whole blood ex-vivo was assayed by Real Time PCR as modified from Manna et al., (2006) using the primers and 
probes represented in Table 1 and the (Taq man system®) [11].  
Table 1. Primers and Probes 
Primer forward Primer reverse Probe (FAM-MGB) 
ȕ-act. 5’CTGGCACCACACCTTCTACAA
3’ 
5’GCCTCGGTCAGCAGCA3’ 5’GCCTCGGTCAGCAGCA3’ 
INFg 5’GCGGAAAAGGAGTCAGAATCT
GT3’ 
5’GCGGAAAAGGAGTCAGA
ATCTGTT3´ 
5’GCGGAAAAGGAGTCAGAATCTG
TT3’ 
IL-2 5’GAAGTGCTAGGTTTACCTCAA
AGC3’ 
5’CAGATCCCTTTAGTTTCA
GAAGTGTTACA3’ 
5’ACACCAAGGAATTAATCAGC3’ 
IL-4 5’GCTCCAAAGAACACAAGCGAT
AAG3’ 
5’CTGCCGCAGTACAGTAGC
A3’ 
5’CTCTGCAGAAGATTTC3’ 
IL-10 5’CCTGGGAGAGAAGCTCAAGAC
3’ 
5’CACAGGGAAGAAATCGG
TGACA3’ 
5’CTGAGACTGAGGCTGCGAC3’ 
L. inf. 5’GGCGTTCTGCGAAAACCG3’ 5’AAAATGGCATTTTCGGGC
C3’ 
5’TGGGTGCAGAAATCCCGTTCA3’ 
Furthermore, the expression of IFN gamma, IL-2, IL-4 and IL-10 were also studied by Real Time PCR 
after in vitro proliferation of PBMC of one dog of the untreated control and one dog of the immunoprophylaxis 
group, at day 667 and parasite load was also obtained by absolute quantification-Real Time PCR [11].  
For statistical analysis means were compared by ANOVA analysis simple factorial test and by one way 
ANOVA- Tukey´s honestly significant difference method (SPSS for windows). To test the significance of the 
differences between groups we also used the 95% confidence interval of the averages. All the animals included in 
this investigation were treated following the guidelines for animal experimentation of the USA National Institute of 
Health, and experiments were done in accordance with the institutional guidelines in order to minimize animal 
suffering. 
The results of the serological survey are summarized in Figure 1
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Figure 1. Evolution of the anti-FML and anti-NH36 serological response in dogs treated for prophylaxis or 
immunotherapy with the VR1012-NH36 DNA vaccine. 
The serological immune response against FML and NH36 only started after the infective challenge, 
meaning that seropositivity is not a consequence of NH36 DNA vaccination. This is a very beneficial effect of the 
vaccine that can be potentially used in the field for the control of CVL. As a canid zoonoses, the epidemiological 
campaign removes for sacrifice dogs seropositive to Leishmania for they are considered infected and reservoir of 
disease [12]. The ANOVA analysis of the anti-FML response showed significant differences between times 
(ANOVA  p= 0.000) but not by treatments (p> 0.05) since anti-FML antibodies increased in both vaccinated 
(prophylaxis and immunotherapy) and control dogs simultaneously. The serological response against the NH36 
recombinant protein was, conversely, specifically increased in both prophylaxis and immunotherapy treated dogs 
(ANOVA p= 0.000) while remained low in infected animals. This is another beneficial effect of the DNA vaccine 
that discriminates the infected from the vaccinated animals. 
The results of clinical, parasitological and cell immune responses of dogs vaccinated with the NH36 DNA 
vaccine and untreated controls are summarized in Table 2. 
Table 2. Clinical, parasitological and cell immune response results in dogs vaccinated with the NH36 DNA vaccine.
For all variables, the results are shown as the average and CI95% values recorded during the 17 months 
period of the experiment (Table 2). Only the results of parasite/lymphocyte ratio at lymph nodes were recorded at 
day 307 after the initial vaccine dose. Animals were monthly clinically evaluated. A score of the clinical signs was 
prepared. We considered the diameters of small (up to 1cm); medium (1-1.5cm) and large lymph nodes (≥2cm) and  
loss of weight was considered mild (0-2kg), medium (3-5kg), severe (6-8kg) and extremely severe (≥9kg). While  
asymptomatic cases receive value=0, to the detection of alopecia, onycogryphosis, skin lesions or conjunctivitis was 
Treatment Symptom 
scores 
Parasite/lym
phocyte ratio 
DTH CD4+* CD8+* Average time of survival 
(days) 
Prophylaxis 39.4 
(57.7-21.10) 
0.64 
(1.93-0.65) 
7.18 
(8.30-6.07) 
42.00 
(46.31-37.69) 
22.98 
(29.63-16.34) 
343.25 
(211.42-473.08) 
Immunotherapy 44.4 
(69.62-19.19) 
1.18 
(2.96-0.60) 
5.76 
(8.44-3.08) 
43.27 
(47.31-39.24) 
24.99 
(34.64-15.30) 
367.33 
(238.40-496.26) 
Saline control 58.4 
(80.4-36.40) 
2.05 
(4.01-0.01) 
3.18 
(5.55-0.80) 
32.10 
(38.97-25.23) 
26.52 
(34.12-18.92) 
278.60 
(166.56-390.64) 
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attributed value = 1; to anaemia or oedema was attributed value=2;  to ictericia, cachexia, cough, asthenia, cataract 
or nasal purulent secretion was attributed value = 4 and to death caused by CVL was attributed value =10. The 
scores for normal undetectable, small, medium and enlarged lymph nodes were= 0,1,2,3, respectively, and a score of 
= 2,3,4 or 5 was attributed, respectively, to mild, medium, severe and extremely severe loss of weight. The CD4+ 
and CD8+ lymphocyte proportions correspond to the counts obtained after in vitro proliferation with NH36. 
As expected for the development of CVL, the analysis of the CI95% showed that, the untreated controls 
developed more symptoms, higher parasite/lymphocyte ratio, smaller DTH reactions, lower proportions of NH36-
specific CD4+ cells, and sustained NH36-specific CD8+ cell counts, when compared to dogs of the prophylaxis 
group disclosing the protective potential of preventive vaccination with the VR1012-NH36 DNA vaccine. 
In the immunotherapy treated group, enlarged DTH reactions, enhanced CD4+ and sustained CD8+ 
lymphocyte proportions were also detected, however, without reduction of symptoms or parasite/lymphocyte ratio, 
when compared to the untreated controls indicating the NH36 DNA vaccine, as 3 doses of 750ug/each was not 
sufficiently potent to control the disease provoked by 7 x 108 amastigotes obtained from a dog infection. Future 
experiments should be done with smaller infective doses such as those used in other investigations [13] (5 x 106 in 
vitro cultured promastigotes) in order to better define the immunotherapeutic potential of the vaccine. The high 
infective challenge used in this investigation was also responsible for the detected high mortality (Table 2). In spite 
of that, it was possible to see a delay in mortality rates generated by the vaccine. Indeed, the average time of survival 
of dogs treated for prophylaxis and immunotherapy was 64.65 and 88.73 days higher, respectively, than that of 
untreated controls (Table 2), confirming the preventive and therapeutic effect of the NH36 DNA vaccine.  
At the end of the experiment (day 490), the Leishmania parasite load (Figure 2A) and the cytokine 
expression (Figure 2B) were assayed in PBMC and whole blood, respectively, from one dog of the prophylaxis and 
one dog of the control group, by PCR Real Time techniques. Also, the cytokine expression was measured after in 
vitro proliferation of PBMC of one control and one dog of the prophylaxis group, at day 667 (Figure 2C). 
  
Figure 2. Parasite load obtained by absolute quantification-Real Time PCR in whole blood ex-vivo (A) and IFN 
gamma, IL-2, IL-4 and IL-10 expression in PBMC ex vivo (B), and after in vitro proliferation with 0.5 ȝg NH36 (C), 
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of individual dogs. In (A) the bars represent the number of promastigotes in 2 x 106 PBMC, according to a 
Leishmania infantum promastigote standard-curve ranging from 101 to 106, while in (B) the results of cytokine 
expression  are expressed as relative quantification = log2 Delta (Ct of each cytokine–Ct of ȕ actin) x 100 and in (C), 
to delta Ct (Ct of each cytokine–Ct of ȕ actin) [manna 2006].  
At day 490, the parasite load of an untreated survivor control dog (638.05 parasites) felt outside the IC95% 
of that of vaccinated dogs (32.02, IC95% 9.45-64.59) (Figure 2A), either by prophylaxis or by immunotherapy 
suggesting that both vaccination treatments succeeded in reducing the Leishmania infective burden provoked by an 
artificially high parasite challenge of 7 x 108 infective amastigotes. Accordingly, the untreated control dog showed a 
IFN Ȗ-ȕ actin relative quantification (191.72) lower than the average of vaccinated dogs (220.79) although  did not 
felt outside their IC95% (182.34-259.25) (Figure 2B). The IL-2 and IL4 relative quantifications for control dog 
were 219.91 and 210.80, respectively, and were higher for vaccines: 258 (IC95% 226.53-289.50) and 250.85 
(IC95% 213.71-287.98) indicating the global enhancement of the secretion of IFN- Ȗ, IL-2 and IL-4 due to NH36 
DNA vaccination treatment. When measuring the cytokine expression of the NH36 specific-lymphocytes after in 
vitro incubation (Figure 2C) an increase in IFN-Ȗ, IL-2 and IL-4 and a decrease in IL-10 expression were observed 
in the vaccinated dog (prophylaxis) relative to the untreated control dog, indicating the presence of a TH1 cell 
immune response. The decrease in IL-10 after vaccination is a promising result since this cytokine is related to 
progression to severe CVL [11]. 
From the analysis of our results we conclude that the VR1012-NH36 vaccine induces strong prophylactic 
protection and a milder immunotherapeutic effect against a high dose canine experimental infection with 
Leishmania chagasi.
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